Peptika.
Cat. 02
Type I · Lyophilised
PK-2026-THYMAL
Peptika Thymalin vial
Lot-tracedEU pharmacyCold-chain 2–8 °C
02 · Longevity & Anti-aging

Thymalin.

Thymus-derived peptide complex — immune homeostasis in ageing.

Select strengthPer-vial price
Quantity
1
Total
€50.00· 1 vial

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

  • Magistral preparation — Directive 2001/83/EC Art. 5(1).
  • Patient-named prescription only — dispensed against a valid Rx.
  • EU-GMP Annex 1 Grade A/B cleanroom compounding.
  • Cold-chain shipping across EU/EEA — 2–5 working days.
Overview

About Thymalin.

Thymalin is a polypeptide complex extracted from the thymus, studied since the 1970s in Soviet and Russian geriatric research. It is principally used to support immune homeostasis in older adults.

It is part of the same Russian peptide-bioregulator school as Epithalon. The clinical literature is dense but mostly outside the standard EMA/FDA framework.

Mechanism of action

Thymalin modulates T-cell differentiation, restoring a more youthful CD4/CD8 ratio and increasing natural killer cell activity. It also appears to influence hormonal axes downstream of the thymus.

Posology · for information only

Subcutaneous injection, typically 10–20 mg per day for 5–10 day courses, repeated 2 times per year.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence baseClinical case-series evidence
Indications studied
Thymic functionImmune balanceGeroprotection
Identification & specifications
INN / Name
Thymalin
Form
Lyophilised vial · subcutaneous injection
Strength
5mg vial
Manufacturing
EU-GMP Annex 1 · Grade A/B
Endotoxins
European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity
HPLC + MS · > 98%
Cold chain
Validated 2–8 °C, monitored end-to-end
Regulatory basis
Directive 2001/83/EC · Article 5(1)
Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.